XTalks

NOVEMBER 15, 2024

These RXR receptors play a key role in regulating transcription pathways involved in inflammation and immune responses, among other cancer hallmarks, to modulate the tumor microenvironment. Tamibarotene is a selective agonist of retinoic acid receptor alpha/beta, with potential binding to retinoid X receptors (RXR).

Trials 105

Trials HR Immune Response FDA Approval 105

XTalks

DECEMBER 30, 2024

has announced promising Phase IIb results for cenerimod, an investigational drug targeting immune system dysfunction in moderate-to-severe systemic lupus erythematosus (SLE). SLE is an autoimmune disease where the immune system attacks healthy tissues, causing inflammation, pain and potential organ damage. Viatris Inc.

Immune Response 52

Immune Response Gene Expression Drugs Trials 52

XTalks

DECEMBER 29, 2023

Tarlatamab is an investigational drug currently undergoing clinical trials to assess its efficacy in patients with two distinct types of neuroendocrine cancer: SCLC and neuroendocrine prostate cancer (NEPC). As a bispecific T-cell engager immunotherapy, tarlatamab directs the patient’s T cells to attack cancer cells exhibiting DLL3.

Clinical Trials 119

Clinical Trials Clinical Trials FDA Approval Trials 119

XTalks

AUGUST 8, 2022

Medicxi is a prominent international life sciences investment firm that invested in over 60 portfolio companies such as Versanis Bio, Rivus Pharmaceuticals, Capella Bioscience and more. One of Medicxi’s portfolio companies called MiroBio is set to be acquired by Gilead Sciences for approximately $405 million in cash.

Immune Response 98

Immune Response Antibody Life Science Engineer 98

pharmaphorum

JULY 18, 2022

MBA, managing director at CanSino Biologics Europe, tells us about Convidecia, a single dose SARS-CoV-2 vaccine offered as an injectable and inhalant that allows ease of storage, an alternative option for individuals with needle phobias, and robust elongated CD4 and CD8 cellular response. Morgon, PharmD, LL.M, The inhalant version.

Vaccine 138

Vaccine Vaccination Development Immune Response 138

XTalks

NOVEMBER 5, 2024

Its lead candidate, PL-14, targets nasal allergies and is scheduled for US Food and Drug Administration (FDA) submission via the 510(k) pathway, with preclinical trials expected to start in the second quarter of 2025 and pivotal trials by the end of 2025.

Drug Delivery 111

Drug Delivery Drugs Immune Response Allergies 111

XTalks

JANUARY 8, 2021

Both vaccines demonstrated an effectiveness of about 95 percent in Phase III clinical trials. Others have voiced concern that clinical trials have not evaluated half doses nor different dosing schedules. The agency says, “These are all reasonable questions to consider and evaluate in clinical trials.

Vaccine 144

Vaccine Vaccination Clinical Trials Clinical Trials 144

pharmaphorum

AUGUST 27, 2020

The Biotechnology and Biological Sciences Research Council (BBSRC), part of UK Research and Innovation (UKRI), works with universities, research organisations, businesses, charities, and government to develop a supportive ecosystem. The common challenge is undertaking lengthy and capital-intensive phase II/III clinical trials.

Vaccine 122

Vaccine Vaccination Life Science Clinical Trials 122

XTalks

JANUARY 20, 2025

Sasanlimab, a subcutaneous anti-PD-1 therapy, offers a novel immunotherapy approach that enhances the anti-tumor immune response. Having its own checkpoint inhibitor to combine with its ADCs rather than from other companies would make things easier to coordinate in clinical trials.

Antibody 52

Antibody Trials Clinical Trials Clinical Trials 52

XTalks

AUGUST 13, 2020

As the rush for a COVID-19 vaccine continues, healthcare services company Kaiser Permanente has joined in on the clinical testing of Pfizer Inc. and BioNTech’s lead vaccine candidate in a Phase III trial being conducted at sites in California and Oregon. Kaiser began Phase III trials of the vaccine at the end of July.

Vaccine 89

Vaccine Vaccination Trials Clinical Trials 89

XTalks

JANUARY 20, 2025

Sasanlimab, a subcutaneous anti-PD-1 therapy, offers a novel immunotherapy approach that enhances the anti-tumor immune response. Having its own checkpoint inhibitor to combine with its ADCs rather than from other companies would make things easier to coordinate in clinical trials.

Antibody 52

Antibody Trials Clinical Trials Clinical Trials 52

The Pharma Data

JANUARY 3, 2021

. This trial is the first to evaluate nasally administered Foralumab to improve the immune system’s fight against coronaviruses. Furthermore, nasal anti-CD3 dampens cytotoxic CD8 T cell responses that are known to cause lung damage in COVID-19 patients.”. About Tiziana Life Sciences. .

Life Science 40

Life Science Clinical Trials Clinical Trials Antibody 40

XTalks

APRIL 26, 2021

Moreover, a very strong immune response is needed to fend off the disease. The vaccine is protein-based and contains an adjuvant (MM), a component that helps generate a stronger immune response, that was developed by Novavax. Malaria Vaccine Phase II Trial. At six months, 29.5

Vaccine 105

Vaccine Vaccination Immune Response Trials 105

Pharmaceutical Technology

NOVEMBER 22, 2022

The mission was first put forward during the UK’s G7 Presidency of June 2021, with support from representatives of the life sciences industry. billion towards the “pandemic-busting plan”, which involves the investigation of rapid response vaccine technologies. The UK Government is behind this effort.

Manufacturing 130

Manufacturing Vaccine Vaccination RNA 130

XTalks

NOVEMBER 30, 2023

The safety and efficacy of Cabenuva were established through two randomized, open-label, controlled clinical trials involving 1,182 HIV-infected adults who were virologically suppressed (HIV-1 RNA less than 50 copies/mL) before initiating Cabenuva treatment. Additionally, Gag-specific CD8+ T cells demonstrated an increase of 1.7

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

XTalks

NOVEMBER 23, 2020

The global trials are assessing the safety and efficacy of the vaccine in individuals aged 18 years or over from diverse racial and geographic groups who are healthy or have stable underlying medical conditions. Oxford-AstraZeneca COVID-19 Vaccine Induces Immune Responses in Early Clinical Trials.

Vaccine 97

Vaccine Vaccination Clinical Trials Clinical Trials 97

pharmaphorum

NOVEMBER 29, 2022

Number of on-going clinical trials: 14. T cells are known to mediate anti-tumor immune responses. For that reason, they have become the key target of immune checkpoint therapies, like PD-(L)1 agents. Locations: 3 (US HQ, Korea office, Korea R&D center). Number of employees: 90+ (as of Oct. Creation: Jan.

Clinical Trials 105

Clinical Trials Clinical Trials Trials Engineer 105

XTalks

OCTOBER 11, 2024

The vaccine uses recombinant RSV glycoprotein F, stabilized in its prefusion conformation (RSVPreF3), along with GSK’s AS01E adjuvant to boost the immune response — the same adjuvant used in Shingrix, its shingles vaccine, but at a lower dose.

Vaccine 103

Vaccine Vaccination Immune Response Trials 103

XTalks

SEPTEMBER 5, 2023

Investigation of the possibility of VAED is crucial during clinical trials for decision-making on vaccine licensing by regulatory agencies. In the majority of cases, the risk of VAED is brought to light during preclinical stages or early clinical trial phases.

Vaccine 96

Vaccine Vaccination Development Clinical Trials 96

XTalks

JULY 31, 2024

Alopecia areata can be triggered by genetics, immune system dysfunction and environmental factors. Leqselvi works by selectively inhibiting the Janus kinases (JAK) JAK1 and JAK2, pathways that play a key role in this misguided immune response.

Immune Response 105

Immune Response Dermatology Clinical Trials Clinical Trials 105

XTalks

NOVEMBER 22, 2022

In clinical trials, the treatment delayed stage 3 disease onset for about two years compared with the placebo. Tzield’s FDA approval was based on safety and efficacy data from a randomized, double-blind, event-driven, placebo-controlled trial involving 76 patients with stage 2 type 1 diabetes.

Insulin 97

Insulin Drugs FDA Approval Immune Response 97

XTalks

DECEMBER 14, 2021

Moderna revealed the first interim results from a small, Phase I study of its mRNA-based influenza vaccine, which showed that the vaccine had no significant safety concerns and elicited immune responses against four strains of the influenza virus. There were no significant safety findings reported through day 29. Mixed Results.

Vaccine 98

Vaccine Vaccination Immune Response Antibody 98

XTalks

JULY 28, 2021

While Merck’s previous shot, Pneumovax 23, defends against 23 serotypes and has been on the market for almost four decades, the immune responses it generates are not as durable as Prevnar 13. This is why Pfizer’s Prevnar 13 has dominated the pneumonia vaccine space for more than a decade.

FDA Approval 89

FDA Approval Vaccine Vaccination Immune Response 89

XTalks

SEPTEMBER 15, 2020

A vaccine developed by Swedish company Diamyd Medical has demonstrated significant treatment efficacy in a predefined genetic subgroup of individuals with type 1 diabetes in a Phase IIb clinical trial. How the Type 1 Diabetes Vaccine Works. islet cells of the organ, giving rise to the disease. cells of the pancreas.

Vaccine 103

Vaccine Vaccination Insulin Trials 103

XTalks

JANUARY 20, 2021

While diseases like celiac are associated with inappropriate activation of the immune system triggered by food antigens, this is not the case in IBS. In a normal, healthy intestine, foods do not trigger immune responses and so in a patient with IBS, something else must activate the response. Mouse and Human Studies.

Immune Response 52

Immune Response Research Allergies Protein 52

XTalks

MARCH 2, 2021

S) over the weekend, shortly after evaluation of study data from trials of the vaccine by the agency. The AAV serves as a vector to carry the gene into cells from which the spike protein fragment is made to elicit an immune response. Janssen Inc.,

Vaccine 98

Vaccine Vaccination Trials Clinical Trials 98

XTalks

JUNE 18, 2021

This is why Regeneron’s announcement of positive clinical trial results that show its antibody cocktail treatment can cut deaths among hospitalized patients is welcome news. It is the first trial to demonstrate that any antibody treatment could improve survival in patients hospitalized with COVID-19.

Antibody 75

Antibody Immune Response Trials Clinical Trials 75

XTalks

MAY 7, 2021

Novavax published the latest results from a Phase IIb clinical trial conducted in South Africa evaluating the safety and efficacy of NVX-CoV2373, appearing in the NEJM ’s May 6, 2021 issue. 1.351 variant. The results show that the COVID-19 vaccine candidate has an efficacy of 51 percent against the B.1.351

Protein 97

Protein Vaccine Vaccination Trials 97

The Pharma Data

NOVEMBER 1, 2020

Clinical Data Expected by End of Year. Tiziana Life Sciences plc. (“Tiziana” or the “Company”). This clinical trial will be coordinated by the team at the INTRIALS, a leading, full-service Latin America Clinical Research Organization (CRO), based in Sao Paulo City, Brazil.

Clinical Trials 40

Clinical Trials Clinical Trials Antibody Life Science 40

XTalks

JUNE 15, 2022

Adjuvants can help boost the effectiveness of a vaccine and elicit a stronger immune response. Clinical Trial Results. Results from the PREVENT-19 pediatric expansion trial showed that the vaccine was also effective in adolescents aged 12 to 17 years. NVX-CoV2373 also includes an adjuvant called Matrix-M.

Vaccine 59

Vaccine Vaccination Immune Response Protein 59

pharmaphorum

SEPTEMBER 22, 2022

Le Vert says Osivax’s technology differs, however, as it attacks the virus’ T-cells, making the vaccine more effective in the long term, and that clinical trials have shown promise. The beauty of that T-cell response is that you can actually access the internal parts of the virus,” Le Vert states.

Vaccine 97

Vaccine Vaccination Antibody Clinical Trials 97

XTalks

JULY 2, 2021

The CDC says that while “clinical trials that study the safety of COVID-19 vaccines and how well they work in pregnant people are underway or planned … based on how these vaccines work in the body, experts believe they are unlikely to pose a risk for people who are pregnant.”.

Vaccine 105

Vaccine Vaccination Protein Immune Response 105

XTalks

JUNE 5, 2023

Abrysvo functions as a vaccine by triggering an immune response specifically aimed at RSV preF, which provides protection against RSV-induced LRTD. Safety and Efficacy of Abrysvo The FDA’s approval of Abrysvo is supported by compelling clinical evidence. percent and severe RSV-associated LRTD by 94.1

Vaccine 98

Vaccine Vaccination FDA Approval Protein 98

XTalks

JULY 8, 2021

Patients with severe COVID-19 often have an overactivation of the immune system, which involves the increased release of cytokines (cytokine release syndrome) such as IL-6. By blocking the cytokine from binding to its receptor, the hyperactive immune response can be tamed. Monoclonal antibodies generally do not come cheap.

Doctors 98

Doctors Doctor Drugs Manufacturing 98

XTalks

MAY 30, 2023

Novel treatments: Ongoing research into new treatments for MS include novel immunomodulatory drugs that aim to modulate or suppress the immune response that attacks the myelin sheath in MS. Clinical trials have shown that HSCT can halt disease progression in some people with aggressive forms of MS, although it is a high-risk procedure.

Genetics 98

Genetics Research Immune Response Drugs 98

Delveinsight

FEBRUARY 11, 2021

Verily collaborates with Janssen to launch COVID-19 immune response study. Verily is partnering with Johnson & Johnson’s Janssen division to witness the body’s earliest immune responses to a coronavirus infection, with people participating in the research from within their homes. .

Gene Therapy 52

Gene Therapy Gene Immune Response In-Vivo 52

pharmaphorum

OCTOBER 12, 2022

Similar to how we injected mRNA into people to trigger an immune response and train their immune system against COVID-19, genomic medicine repairs cellular or molecular mechanisms that are dysfunctional and cause disease.”. Debiopharm is interested in innovative therapeutic platforms for tomorrow,” Gibbs says. “We

Genome 105

Genome Genomics Medicine Development 105